Psychiatrist.comLost in Translation: The Value of Psychiatric Clinical Trials

After supporting a number of significant clinical trials in psychiatry more than ten years ago, NIMH abruptly shifted its approach and began allocating 90% of its money to neuroscience. The policy is still in place even though this “has yet to deliver major clinical gains.” Clinical advancement has been halted as a result of the devaluation of mental clinical trials and the meticulously designed, essential methodologies they demand.